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Preeclampsia (PE) is one of the main causes of maternal and fetal morbidity and mortality in the world, causing nearly 40% of
births delivered before 35 weeks of gestation. PE begins with inadequate trophoblast invasion early in pregnancy, which produces
an increase in oxidative stress contributing to the development of systemic endothelial dysfunction in the later phases of the
disease,leadingtothecharacteristicclinicalmanifestationofPE.NumerousmethodshavebeenusedtopredicttheonsetofPEwith
diﬀerentdegreesofeﬃciency.Thesemethodshaveusedfetal/placentalandmaternalmarkersindiﬀerentstagesofpregnancy.From
an epidemiological point of view, many studies have shown that PE is a disease with a strong familiar predisposition, which also
varies according to geographical, socioeconomic, and racial features, and this information can be used in the prediction process.
Large amounts of research have shown a genetic association with a multifactorial polygenic inheritance in the development of this
disease. Many biological candidate genes and polymorphisms have been examined in their relation with PE. We will discuss the
most important of them, grouped by the diﬀerent pathogenic mechanisms involved in PE.
1.Introduction
Preeclampsia (PE) and its complications and associated pa-
thologies have become one of the main causes of maternal
and fetal morbidity and mortality in the world, causing
nearly 40% of births delivered before 35 weeks of gestation.
Moreover, PE has been strongly associated with an increased
risk of later-life death due to cardiovascular disease, inde-
pendent of other risk factors [1–3]. PE is present in around
5–10% of all pregnant women worldwide and despite the
amount of resources invested in the research and treatment
of this pathology, its development is still barely predictable
and thus challenging to prevent and manage clinically.
PE constitutes a clinical spectrum that includes “mater-
nal” PE and “placental” PE [4]. In general, placental PE in-
volves an abnormal placentation in a healthy woman, and in
maternal PE there is a normal placentation in a woman with
a preexistent pathology, like cardiovascular disease, chronic
arterial hypertension, or diabetes. Nevertheless, in practice,
the great majority of patients who will develop PE have
both types to diﬀerent degrees, and rather than being two
distinct types of disease, they are the extremes of the same
pathologic entity. These 2 origins may explain the variability
in the severity and gestational age of presentation of this
syndrome.PlacentalPE,withapoortrophoblasticperfusion,
generates oxidative stress, with liberation of trophoblast
factors to maternal circulation, which will induce a sec-
ondary inﬂammatory response and endothelial dysfunction
[5]. In maternal PE, an inﬂammatory response takes place,
involving all the inﬂammatory components of circulation,
including the endothelium [5].
The understanding of the underlying factors that explain
the pathogenesis of PE and the early identiﬁcation of the
patients at risk of the disease will help in the development
of preventative or early therapeutic interventions, aimed
to reduce the associated morbidity and mortality during
pregnancy, but also the long-term severe problems that PE
may produce or is associated with.2 Journal of Pregnancy
2. Pathogenesis of PE:
APlacentalOriginatedDisease
Despite the breakthroughs in the understanding of the path-
ogenesisofPE,themechanismsthatﬁnallytriggerthedisease
are still not clearly elucidated. Nevertheless, it seems clear
that the development of PE during pregnancy requires the
presence of the placenta, given that this clinical syndrome
will not be developed if it is not present, and it disappears
soon after placental delivery [6]. In placental PE, it is also
widely accepted that the physiopathological process of
PE begins with inadequate trophoblast invasion early in
pregnancy, which produces an increase in oxidative stress
contributing to the development of systemic endothelial
dysfunction in the later phases of the disease, leading to the
characteristic clinical manifestation of PE, with hyperten-
sion, proteinuria, and edema.
During normal placentation, the cytotrophoblast cells
form a highly invasive extravillous trophoblast (EVT) that
can migrate into the decidua and invade the ﬁrst third of the
myometrium, inducing the remodelling of spiral arterioles
to produce the low-resistance vascular system that allows a
10-fold increase in blood ﬂow, essential for fetal growth [7–
9]. The relative reduction of uteroplacental ﬂow, secondary
to abnormal placentation caused by an impaired trophoblast
invasion[8],isthetriggerforthedevelopmentofPE[10–12].
This was ﬁrst highlighted by the histopathological ﬁndings
in the site of placental implantation, where 80 to 100% of
patients with PE have a deﬁcit of the physiological invasion
of the maternal spiral arteries by the EVT [8, 13]. It has
been postulated that the physiological changes that favor the
invasive phenotype of these cells are due to the exposure of
cytotrophoblast cells to a hypoxic environment. The normal
concentration of oxygen in the ﬁrst trimester placenta is only
about 3% O2 (±18mm Hg) and this low oxygen milieu
is believed to facilitate trophoblast invasion [14]. In the
normal placentation process, the cytotrophoblast invasion is
regulated by the gradient of oxygen concentration between
the placenta and maternal arteries. Therefore, the hypoxic
environments that face the cytotrophoblast at the begin-
ning of the placentation change gradually to a normoxic
environment as invasion takes place [15]. In pathologies
with an abnormal placentation, the trophoblastic invasion is
poor and limited only to spiral arteries present in superﬁcial
decidua. The mechanisms involving this poor placentation
are still areas of research.
In summary, the events that lead to the development of a
PEmaybeexplainedbyaﬁrststageofdefectivetrophoblastic
invasion, which occurs early in pregnancy, with uteropla-
cental circulation remaining in a state of high resistance
during pregnancy, which can be detected by an increased
resistance of the uterine arteries [16]. The persistence of
a state of underperfusion produces placental hypoxia and
local oxidative stress, resulting in a systemic inﬂammatory
response and endothelial dysfunction, leading to the onset of
the clinical symptoms of PE [4]. The ﬁrst stage is diﬃcult
to diagnose, while the second is the clinical syndrome
itself.
3. Prediction of PE
Numerous methods have been used to predict the onset
of PE with diﬀerent degrees of eﬃciency. These methods
have used fetal/placental and maternal markers in diﬀerent
stages of pregnancy in order to predict the disease. The
fetal/placental markers could be divided in (1) trophoblast
invasion (PLGF, IGFBP-1, PAPP-A, Doppler ultrasound, and
HLA-G), (2) placental hypoxia (sFlt-1, VEGF, PLGF), (3)
reactive oxygen species (lipid peroxide), and (4) placental
function (activin/inhibin, CRH/CRHBP, and PAI-2). The
maternal markers that have been used could be classiﬁed as
(1) metabolic syndrome (BMI, Leptin, insulin, and glucose),
(2)endothelialfunction(PAI-1,Fibronectin,VCAM/ICAM),
(3)prooxidants(8-epi-PGF2a),(4)antioxidantreserve(vita-
mins C and E), and (5) immune function (AT-R autoanti-
bodies) [17].
Despite the improvements in the prediction of the dis-
ease, there is no treatment that reverses this pathology once
it has begun. This is mainly explained by the fact that the
diﬀerent tests used to predict PE have a better performance
after the ﬁrst trimester of pregnancy, a period in which the
intervention to decrease the prevalence of the disease has
proved to be ineﬀective [18]. This is why more research is
needed to develop clinical tools that allow a prediction in
even more early stages, or even before the patient gets
pregnant. Moreover, it should be noted that the PE has a
clear genetic component and each of the etiological factors
thatareinvolvedinitspathogenesis,immunemaladaptation,
placental ischemia, or oxidative stress may have a genetic
implication [19].
4. The GeneticComponent
From an epidemiological point of view, many studies have
shown that PE is a disease with a strong familial predisposi-
tion, which also varies according to geographical, socioeco-
nomic, and racial features. It has been reported that women
with ﬁrst-degree relatives with PE have 5 times more risk
of developing the disease, while those with second-degree
relatives have their risk doubled [20, 21]. Moreover, it is
believed that paternal genes also play an important role in
the development of PE. This is evidenced by the increased
risk of PE in women with pregnancies of men who have
previously been involved in pregnancies complicated with
PE [22, 23]. This is of special importance since genomic
imprinting results in involvement of paternal genes in the
control of invasion and placental growth, whereas maternal
genes inhibit it and are responsible for the adaptive immune
response of pregnancy [24]. A large genetic association study
of PE was published by Goddard et al. [25] that reported
a study evaluating 775SNPs in 190 genes in more than
350PE mother and oﬀspring pairs and 600 control pairs.
They detected six genes with a signiﬁcative maternal-fetal
genotype interaction related to PE in IGF1, IL4R, IGF2R,
GNB3, CSF1,a n dTHBS4. These ﬁndings and others suggest
a multifactorial polygenic inheritance with a genetic compo-
nent in the development of this disease [26, 27].Journal of Pregnancy 3
Table 1: Overview of the diﬀerent polymorphism described.
Gene Function SNP Reference
ERAP 1-2 Aminopeptidases 1-2. Related to immune antigen presentation p.392K>N and p.669L>Q[ 28]
TNFSF13B Regulation of immune response, member of tumor necrosis
factor family
rs16972194
rs16972197
rs56124946
[29]
HLA-G Member of HLA class I molecule and has immunosuppressive
properties G∗0106 HLA-G [30]
VEGF Modulates the cell cycle, migration, and diﬀerentiation
rs1485766
rs6838834
rs7664413
rs2010963
+936 C>T
[31, 32]
Flt-1 FMS-related tyrosine kinase. It shows tyrosine protein kinase
activity
rs12584067
rs7335588
rs722503
[31]
eNOS Endothelial nitric oxide synthase p.Glu298As-786T>C[ 33]
CYP11B2 Steroid 11/18-beta-hydroxylase −344C/T[ 34, 35]
Prothrombin (F2) Increases blood viscosity and the likelihood of thromboembolic
events G20210A [36]
Factor V Coagulation factor V 1691G>A[ 36–38]
SERPINE1 Endothelial plasminogen activator inhibitor-1 (PAI-1), the
major inhibitor of ﬁbrinolysis 4G/5G polymorphism [39]
MTHFR Methylenetetrahydrofolate reductase rs1801133
A1298C [40–46]
MTRR Methionine synthase reductase rs1801394 [40–43, 46, 47]
MTR Methyltetrahydrofolate-homocysteine S-methyltransferase g.2756A>G[ 48–50]
SNP: single nucleotide polymorphism.
Many biological candidate genes and polymorphisms
have been examined in its relation with PE. We will discuss
some of them, grouped by the diﬀerent pathogenic mecha-
nisms involved in PE (see Table 1).
4.1. Immune Maladaptation
4.1.1. ERAP1 and 2. The endoplasmic reticulum aminopep-
tidases 1 and 2 (ERAP1 and 2) are important in the immune
response in terms of the antigen presentation [51] and they
are colocalized within the endoplasmic reticulum (ER). The
process starts with a proteolysis by the proteosome in the
cytosol, and ﬁnally N-extended peptides are processed by
aminopeptidase to mature the epitope which is presented
by MHC class I. Data in mice have shown that ERAP1
trims MHC class I presented peptides in vivo and is the
major trimming enzyme in the ER lumen; however ERAP2
also plays a role in the trimming of proteins [52]. In a
murine model, it has been demonstrated that ERAP1 can be
secreted in response to LPS/INFγ and activate macrophages
in culture [53]. In human placenta, aminopeptidase RNA of
ERAP1 has been detected by RT-PCR [54]. Recent studies
in Australian/New Zealand and Norwegian populations
have shown that ERAP2 SNPs (p.392K>N and p.669L>Q;
rs2549782 and rs17408150, resp.) are associated with PE
susceptibility [28]. Recently, these SNPs have been also
associated with increased risk of hypertensive disorders in
pregnancy in African American population, but not in a
Chileanone[55],supporting the ideathatPEhasaheteroge-
neous basis with variation between diﬀerent ethnic group.
4.1.2. TNFSF13B. TNFSF13B is a member of the tumor ne-
crosis factor family of ligands. TNFSF13B is localized in
chromosome region 13q32-q34 and is implicated in the
regulation of immune response to infections, autoimmune
disease, and inﬂammation. In the third trimester of preg-
nancy, human placenta expresses TNFSF13B in villous
cytotrophoblast cells (CT) and mesenchymal cells from vil-
lous core (MC). The receptors for TNFSF13B are expressed
in both tissues [56, 57]. It has been proposed that the
role of TNFSF13B [56] may be to modulate the immune
system of the mother or to help in the development of
fetal immune system. At the placental level, it is believed
that TNFSF13B has an antiapoptotic eﬀect [56]. Recently,
Fenstand et al. [29] have shown a genetic variation of
TNFSF13B, which is correlated with the susceptibility of
PE. In his study, these authors detected three rare SNPs
in TNFSF13B (rs16972194, rs16972197, and rs56124946)
in Australian/New Zealand families with PE, but not in
Norwegian ones. These results suggest that TNFSF13B could
contribute to normal immunological adaptation during
pregnancy, and the presence of these SNPs contributes to an
abnormal placentation in some populations.
4.1.3. HLA-G Gene Polymorphism. This gene, localized in
6p21.3,ismemberofHLAclassImoleculeandhasimmuno-
suppressive properties. This characteristic has been impli-
cated in the modulation of the maternal immune system,
giving a possible inhibiting role during pregnancy when the
mother gets in contact with the fetus [30]. HLA-G polymor-
phismisassociatedwithrecurrentspontaneousabortionand4 Journal of Pregnancy
PE. Moreau et al. [30] analyzed several polymorphisms in
placenta of pregnant women with PE and controls, ﬁnding
a higher frequency of G∗0106 HLA-G polymorphism in
preeclamptic placentas compared with control (21.2% and
6.6%, resp.), suggesting a modulator eﬀect of HLA-G over
pregnancy and the risk of PE.
4.2. Vascular and Endothelial Function
4.2.1. VEGF. The VEGF is a family with seven members,
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F,
andPIGF.VEGF-Cisexpressedmainlyintheheart,placenta,
ovary and embryonic tissues [58]. The receptors of VEGF
named VEGFR-1/Flt-1, VEGFR-2/Flk-1 and VEGFR-3/Flt-4
are VEGF tyrosine kinase receptors. VEGFR-1 has a much
weaker kinase activity and modulates the endothelial cell
cycle. VEGFR-2 is the more important receptor for VEGF
in VEGF-induced mitogenesis and permeability. VEGFR-3
is expressed in lymphatic endothelial cells and participates
in mitosis, migration, diﬀerentiation, and survival cells [58].
Several polymorphisms in VEGF have been correlated with
an increased risk of PE. Polymorphisms in VEGF-A have
been implicated in the risk of PE, and down regulation of
VEGF and VEGFR expression has been also reported in
patients with severe PE [59, 60].
A recent study using an array for 50,000 genecentric
SNPs identiﬁed 124 SNPs in 6 genes related to angiogenesis.
This data indentiﬁed allelic variation of VEGF-C, Flt-1,
and Flt-4 from 606 women (489 African American and
117 white Caucasian). Two VEGF-C SNPs (rs1485766 and
rs6838834) were associated with PE in African American
women and one VEGF-C SNP (rs7664413) was associated
with PE in Caucasian women [31]. This author also high-
lights the association between Flt-1 polymorphism and PE,
showing that two Flt-1 SNPs (rs12584067 and rs7335588)
are associated with PE in black women and other two, Flt-
1 SNP (rs722503) and Flt-4 (rs307826), are more prevalent
in white patients with PE [31]. However, some data have
shown that some polymorphism of VEGF can be protective
forPE.InaHungariancohortofnulliparouspatients,astudy
looking for the VEGF r. 405C > polymorphism has found
that patients with the VEGF 405G allele have less severity of
PE [61]. Nevertheless, a recent study [62] showed that the
VEGF 405G allele (rs2010963) is not associated with PE in
a Mexican population of pregnant women. These diﬀerences
highlight the variability and implications of the presence of
some SNPs in diverse ethnic groups.
Finally, Shim et al. [32] have characterized another poly-
morphism of VEGF in Korean pregnant women using PCR
and restriction fragment length polymorphism assay. The
VEGF +936C>T has been located in the 3 -unstranslated
region (UTR), and it has been associated with PE. However,
the small number of patients in this study precludes making
more general conclusions.
4.2.2. eNOS. The NO is synthesized by endothelial nitric
oxide synthase (eNOS, NOS3) using L-arginine as a sub-
strate. NO is the endothelium-derived relaxing factor and
has a crucial role in the regulation of smooth muscle tone
in the vascular system [63], being a critical element for the
correct blood perfusion of the placenta. Recently, it has been
reported that the activity of eNOS is reduced in patients with
PE [33]. Several polymorphisms have been described for
eNOS, but two of them have been strongly related with PE,
SNP G c.894G>T, which encodes an amino acid substitution
in eNOS (p.Glu298Asp) and −786T>Cp o l y m o r p h i s m .A
study in 844 Colombian pregnant women reported that
patients homozygous for Asp298 (894T) allele have more
risk of PE than women with Glu298 allele [64]. Similarly,
an important correlation has been reported between hyper-
tension and Asp298 genotype in pregnant women of Japan
[65].
4.2.3. CYP11B2. The steroid 11/18-beta-hydroxylase is
encoded by CYP11B2 gene that is located in 8q24.3. The
protein is physically localized in mitochondrias of the zone
glomerulosa of the adrenal cortex, synthesizing the miner-
alocorticoid aldosterone [66]. The −344C/T polymorphism
within 5 regulatory region of CYP11B2 disrupts a putative
steroidogenic factor-1 site, and the homozygosity for SF-
1T/T variant has been reported as a protective factor
against the risk of PE. In contrast, the heterozygous state
is not protective of PE [34]. Moreover, −344C/T polymor-
phism has a strong linkage disequilibrium respect intron
2 polymorphisms in CYP11B2 and contributes to hyper-
tension in subjects with a raised aldosterone-to-renin ratio
[35].
4.3. Thrombophilic Disorders. Thrombophilic conditions are
associated with an increased risk of venous thromboembolic
events during pregnancy; however, there is still controversy
as to whether they may adversely aﬀect other pregnancy
outcomes such as PE [67]. Women with PE have levels
outside the normal range for ﬁbronectin and von Willebrand
factor, that are markers of endothelial cell injury [68], and
recently several polymorphisms of genes coding for vascular
proteins have been associated with PE.
4.3.1. The human Prothrombin (F2). The gene is localized in
chromosome 11p11-q12, and the increase of prothrombin
during pregnancy can neutralize the eﬀect of physiologic
hemodilution, increasing blood viscosity and the likeli-
hood of thromboembolic events [68]. Recently Seremak-
Mrozikiewicsz et al. [36] have shown in Polish population
that a polymorphism of prothrombin (G20210A) could
be associated with an increased risk of developing severe
PE.
4.3.2. Factor V Gene. The gene is localized in the 1q23 impli-
cated in several diseases. Several studies, have suggested
an important correlation between factor V Leiden SNPs
(1691G>A) and the risk of severe PE [37, 38]a n dar e c e n t
meta-analysis has conﬁrmed these ﬁndings [69]. The study
of Seremak-Mrozikiewicsz [36] also showed that 1691G>A
polymorphism contained at least one variant allele A (GA
and AA) in the group of women with severe and mild PE.Journal of Pregnancy 5
4.3.3. SERPINE1 Gene. PE is associated with thrombosis of
the intervillous space of the placenta. The SERPINE1 gene
encodes endothelial plasminogen activator inhibitor-1 (PAI-
1), the major inhibitor of ﬁbrinolysis (member of the serine
protease inhibitor family). Yamada et al. [39] assessed the
associationbetweenPEandthe4G/5Gpolymorphismofthe
PAI1 gene in 115PE patients, 210 pregnant controls, and 298
healthy volunteer controls. The frequency of homozygotes
for the 4G allele was signiﬁcantly higher in the patients than
in the control pregnant women or healthy volunteers. The
4G allele frequency was also signiﬁcantly higher in patients
than in the control groups. However, other studies have not
found the same association [19].
4.4. Metabolism and Oxidative Stress
4.4.1. PON-1. The paraoxonase-1 (PON-1) is a member of
a three-gene family (PON-2 and PON-3), and is located in
chromosome 7 (q21.22). The protein, primarily synthesized
in the liver, has a release into the circulation and is associated
with high-density lipoproteins (HDLs). The principal action
of PON-1 is the protection of acute toxicity and oxidative
stress involved in the development of atherosclerosis. PON-
1 also has a role in the hydrolysis of organophosphate
insecticides and nerve agents [70, 71]. There is evidence that
shows that preeclamptic women have lower levels of serum
HDL, higher level of serum triglycerides, and lower level
of serum Apo-A1 than control women [72], and this has
been correlated with lower PON-1 serum activity [73]. A
studyin3266Caucasianwomenwhowererandomlyselected
from 23 British towns investigated the relation between
PON-1 p.Q192R polymorphism and hypertension. They
did not ﬁnd evidence of an increased risk of hypertension
during pregnancy in carrier patients, but an association was
seen with preterm birth. This polymorphism could reduce
the hydrolysis and modify the redox equilibrium in the
maternal blood [74]. A relation between Pon-1 p.Q192R
and serum oxidized LDL levels has been also reported [72].
Finally, Isbilen et al. [75]r e p o r t e dad i ﬀerential distribution
of PON-1 p.Q192R and L55M polymorphism between PE
and normal patients. The authors detected high levels of
homocysteine concentration in preeclamptic women when
homozygotes for 192RR and 55RR were present.
Iron-induced oxidation and free radical attack of the R-
SH group of diﬀerent maternal plasma molecules like to
aminothiols, including cysteine, homocysteine, and cys-
teinylglycine result in the formation of radical disulﬁdes.
These changes produce disequilibrium in the redox thiol
status, which is displaced to a higher oxidized state [17]. The
level of maternal plasma homocysteine is higher in severe
PE than in mild PE and control groups. Elevated levels
of maternal homocysteine increase the risk for endothelial
dysfunction and atherosclerosis and occlusive vascular disor-
ders [76].
4.5. MTHFR, MTRR, and MTR Genetic Polymorphisms.
Decrease in MTHFR protein levels or activity by diﬀerent
gene variants induces increased levels of homocysteine [40–
42]. The most extensively studied variant in MTHFR gene
is the polymorphism MTHFR g.677C>T (rs1801133), which
changes an alanine to valine in aminoacid 222 (p.A222V)
in the enzyme regulatory domain and causes a thermolabile
enzyme with decreased activity at 37◦Ca n ds oh y p e r h o -
mocysteinemia [40–43]. This reduced activity of MTHFR
due to MTHFR g.677C>T polymorphism may impair the
remethylation pathway [44]. The frequencies for the T-
allele/TT-genotype of MTHFR g.677C>Tp o l y m o r p h i s ma r e
variable in diﬀerent populations, being 0,11/0,00 in African
Americans and 0,59/0,35 in Mexicans, respectively [45].
MTHFR A1298C is another common polymorphism and it
produces the change of glutamate to alanine in aminoacid
429 (Glu429Ala) within the enzyme catalytic domain [40,
46, 47]. In general, the frequency of CC genotype is about
0.1 and C allele frequency is about 0.36 [42]. As with
MTHFR g.677C>T, MTHFR A1298C polymorphism has
been reported to be associated with altered methionine-
homocysteine metabolism (MHM) and increased levels of
homocysteine [41]. Polymorphisms in MTHFR gene and
hyperhomocysteinemia have been associated with recurrent
pregnancy loss, gestational hypertension, placental abrup-
tion and PE [40, 43].
The most common polymorphism in the MTRR gene is
g.66A>G (rs1801394) substitution, changing isoleucine to
methionine in aminoacid 22 (I22M). MTRR g.66A>Gp o l y -
morphism has been associated with reduced activity of
MTRR enzyme resulting in hyperhomocysteinemia and
altering the methylation of DNA [42, 43, 47]. It has also
been observed that the coexistence of the MTHFR g.677C>T
genotype with the MTRR g.66A>Gp o l y m o r p h i s mm a y
exacerbate the eﬀect of the MTHFR variant alone [46].
A common polymorphism in MTR is g.2756A>Gs u b s t i -
tution, which results in an amino acid change of an aspartic
acid to a glycine (p.D919G), at the penultimate position in
a long helix that leads out of the cobalamin domain. Having
theglycineresidueatthispositioncouldhaveaneﬀectonthe
secondary structure of the protein and therefore have func-
tionalconsequence[48–50].Recently,Furnessetal.[50]ha v e
evaluated one-carbon metabolism enzyme polymorphisms
in patients with uteroplacental dysfunction, suggesting that
the maternal and fetal MTR g.2756A>G allele represents an
important risk factor for the development of uteroplacental
insuﬃciency, which includes PE and intrauterine growth
restriction [50]. The potential negative eﬀect of combined
polymorphisms of the MTHFR, MTR,a n dMTRR genes
on plasma homocysteine levels in at-risk population needs
further investigation.
5. Conclusion
PE is a common disease in pregnancy worldwide, causing
substantial short- and long-term morbidity for the newborn
and the mother. PE is a multifactorial disease, where mater-
nal and fetal factors converge to result in a multicomponent
risk. No single factor has been identiﬁed as capable of
determining the disease, and several are needed to trigger
symptoms of PE.
Various studies in diﬀerent populations have identi-
ﬁed maternal polymorphisms associated with PE through6 Journal of Pregnancy
candidate gene approaches. These ﬁndings will need to
be complemented by currently available genome-wide
approaches, evaluation of interaction between genes, genes
and environment, and the contribution of paternal and
embryonic genotypes. Further prospective studies will be
necessary to assess the predictive potential of markers
identiﬁed through these and other strategies.
Despitesubstantialadvancesinunderstandingthepatho-
genesis of PE, the development of simple tests to identify
individuals or populations at risk still remains a substantial
research, epidemiologic, and clinical challenge.
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